ArticleScientific reports2013
Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MTA1 Regulates EMT and BRAF Signaling Networks in Canine Urothelial Carcinoma.International journal of molecular sciences · 2026Article
- Identification of metastasis-associated protein 1 (MTA1) as a new molecular marker for canine urothelial carcinoma.Frontiers in veterinary science · 2025Article
- Mechanistic exploration of bioactive constituents in Gnetum gnemon for GPCR-related cancer treatment through network pharmacology and molecular docking.Scientific reports · 2024Article
- Article
- Article
- Metastasis-associated protein 1-mediated antitumor and anticancer activity of dietary stilbenes for prostate cancer chemoprevention and therapy.Seminars in cancer biology · 2022Review
- Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Dietary stilbenes as modulators of specific miRNAs in prostate cancer.Frontiers in pharmacology · 2022Review
- Grape Powder Supplementation Attenuates Prostate Neoplasia Associated with Pten Haploinsufficiency in Mice Fed High-Fat Diet.Molecular nutrition & food research · 2020Article
- Article
- Interleukin-17 Promotes Migration and Invasion of Human Cancer Cells Through Upregulation of MTA1 Expression.Frontiers in oncology · 2019Article
- In Vitro Anticancer Properties of Table Grape Powder Extract (GPE) in Prostate Cancer.Nutrients · 2018Article
- MTA1 drives malignant progression and bone metastasis in prostate cancer.Molecular oncology · 2018Article
- Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.Cancer medicine · 2017Article
- Tumoricidal activities of pterostilbene depend upon destabilizing the MTA1-NuRD complex and enhancing P53 acetylation in hepatocellular carcinoma.Experimental and therapeutic medicine · 2017Article
- The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.International journal of molecular sciences · 2017Review
- Article
- Review
- Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.Molecular bioSystems · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis-associated protein 1 (MTA1), a negative epigenetic modifier, plays a critical role in prostate cancer (PCa) progression. We hypothesized that MTA1 overexpression in primary tumor tissues can predict PCa aggressiveness and metastasis. Immunohistochemical staining of MTA1 was done on archival PCa specimens from University of Mississippi Medical Center and University of Iowa. We found that nuclear MTA1 overexpression was positively correlated with the severity of disease progression reaching its highest levels in metastatic PCa. Nuclear MTA1 overexpression was significantly associated with Gleason > 7 tumors in African Americans but not in Caucasians. It was also a predictor of recurrent disease. We concluded that MTA1 nuclear overexpression may be a prognostic indicator and a future therapeutic target for aggressive PCa in African American men. Our findings may be useful for categorizing African American patients with a higher probability of recurrent disease and metastasis from those who are likely to remain metastasis-free.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.